Skip to main content

Acurx Pharmaceuticals, Inc. (ACXP)

NASDAQ: ACXP · Delayed Price · USD
4.90
+0.32 (6.99%)
After-hours:Sep 17, 2021 6:19 PM EDT
4.58
-0.53 (-10.37%)
At close: Sep 17, 4:00 PM
Market Cap46.35M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out9.54M
EPS (ttm)-1.19
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume61,968
Open5.14
Previous Close5.11
Day's Range4.56 - 5.23
52-Week Range3.71 - 8.74
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 15, 2021

About ACXP

Acurx Pharmaceuticals is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization (“WHO”), the U.S. Centers for Disease Control and Prevention (“CDC”), and the U.S. Food and Drug Administration (“FDA”). Priority pathogens are those which require new antibiotics to address the worldwide crisis of antimicrobial resistance (“AMR”), as identified by the WHO, CDC and FDA. The WHO recently stated that growing antimic...

IndustryBiotechnology
IPO DateJun 25, 2021
CEODavid P. Luci
Employees2
Stock ExchangeNASDAQ
Ticker SymbolACXP
Full Company Profile

Financial Performance

Financial Statements

News

CEO Spotlight: Acurx Pharmaceuticals in Focus with CEO David Luci Talking Potentially Transformative Phase 2b Trial, ...

Acurx Pharmaceutical's CEO tells Soulstring Media why he thinks 2021-22 can be a breakout year for his companyNew York, New York--(Newsfile Corp. - September 13, 2021) - Acurx Pharmaceuticals (NASDAQ: A...

6 days ago - Newsfile Corp

Acurx Pharmaceuticals to Join the Russell Microcap Index®

STATEN ISLAND, N.Y., Sept. 2, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics...

2 weeks ago - PRNewsWire

Acurx Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

STATEN ISLAND, N.Y., Aug. 31, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics...

2 weeks ago - PRNewsWire

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2021 Results and Provides Business Update

STATEN ISLAND, N.Y., Aug. 16, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics...

1 month ago - PRNewsWire

Acurx Pharmaceuticals to Present at the Emerging Growth Conference on August 18, 2021

STATEN ISLAND, N.Y. , Aug. 12, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotic...

1 month ago - PRNewsWire

Acurx Pharmaceuticals Joins the Antimicrobials Working Group

WASHINGTON, Aug. 5, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (Acurx) to its coalition of companies with the ...

1 month ago - PRNewsWire

Health Holland Awards Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and A...

STATEN ISLAND, N.Y., Aug. 2, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company") a clinical stage biopharmaceutical company developing a new class of antibiotics fo...

1 month ago - PRNewsWire

Acurx Pharmaceuticals to Discuss 2021 Second Quarter Financial Results on August 17, 2021 Conference Call and Provide...

STATEN ISLAND, N.Y., July 28, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics...

1 month ago - PRNewsWire

Acurx Announces Filing of Provisional Patent Application for Ibezapolstat to Treat CDI While Reducing Recurrence of I...

STATEN ISLAND, N.Y., July 7, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company") a clinical stage biopharmaceutical company developing a new class of antibiotics fo...

2 months ago - PRNewsWire

Acurx Announces New Ibezapolstat Data on Anti-Recurrence Mechanisms in CDI at Prominent International Conference

STATEN ISLAND, N.Y. , July 1, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics ...

2 months ago - PRNewsWire

ACURX PHARMACEUTICALS, Inc. Announces Closing of INITIAL Public Offering OF common stock AND FULL EXERCISE OF UNDERWR...

STATEN ISLAND, N.Y., June 29, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) (the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for diffic...

2 months ago - PRNewsWire

Acurx Pharmaceuticals, Inc. announces pricing of $15 Million underwritten Initial public offering of common stock

STATEN ISLAND, N.Y., June 25, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) (the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for diffic...

2 months ago - PRNewsWire

Acurx Pharmaceuticals IPO Registration Document (S-1)

Acurx Pharmaceuticals, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC